Last Updated: November 10, 2026

Patent: 10,065,995

Summary for Patent: 10,065,995

Title:	Protein for affinity-separation matrix
Abstract:	An object of the present invention is to provide a technique to create novel engineered protein ligands that, when immobilized through a lysine residue (its side chain ε-amino group) which allows for efficient immobilization to a carrier, show the optimum binding capacity and binding efficiency to a target molecule. The present invention provides an engineered protein having a sequence obtained by replacing all the lysine residues in Protein A, which is the most typical protein ligand, with other amino acids, and adding lysine at a terminal; and an affinity separation matrix in which such an engineered protein is immobilized on a water-insoluble carrier by reductive amination or the like. This affinity separation matrix is characterized by its high binding capacity to a target molecule even when the immobilized amount of the ligand is small.
Inventor(s):	Shinichi Yoshida, Dai Murata, Shunichi Taira
Assignee:	Kaneka Corp
Application Number:	US14/007,225
Patent Claims:	see list of patent claims

Details for Patent 10,065,995

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	TREMFYA	guselkumab	Injection	761061	July 13, 2017	10,065,995	2032-03-26
Janssen Biotech, Inc.	TREMFYA	guselkumab	Injection	761061	January 28, 2019	10,065,995	2032-03-26
Janssen Biotech, Inc.	TREMFYA	guselkumab	Injection	761061	September 11, 2024	10,065,995	2032-03-26
Janssen Biotech, Inc.	TREMFYA	guselkumab	Injection	761061	March 25, 2025	10,065,995	2032-03-26
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 10,065,995

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
European Patent Office	2690173	⤷ Start Trial
Japan	2017070289	⤷ Start Trial
Japan	WO2012133349	⤷ Start Trial
United States of America	2014107315	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2012133349	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.